8,419 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the second quarter, HoldingsChannel reports. The fund acquired 8,419 shares of the medical research company’s stock, valued at approximately $2,472,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BIO. Nykredit A S acquired a new position in shares of Bio-Rad Laboratories during the second quarter worth approximately $118,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Bio-Rad Laboratories in the second quarter valued at approximately $1,964,000. California State Teachers Retirement System increased its holdings in shares of Bio-Rad Laboratories by 27,700.0% in the second quarter. California State Teachers Retirement System now owns 6,097,105 shares of the medical research company’s stock valued at $1,790,171,000 after purchasing an additional 6,075,173 shares in the last quarter. AlphaGrep UK Ltd bought a new position in Bio-Rad Laboratories in the 2nd quarter worth approximately $249,000. Finally, AXQ Capital LP bought a new position in Bio-Rad Laboratories in the 2nd quarter worth approximately $416,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 0.0%

BIO opened at $369.46 on Tuesday. The firm has a 50 day simple moving average of $345.85 and a 200 day simple moving average of $304.10. Bio-Rad Laboratories, Inc. has a fifty-two week low of $236.73 and a fifty-two week high of $396.23. The company has a market cap of $9.88 billion, a price-to-earnings ratio of 44.78 and a beta of 1.07. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.14 and a quick ratio of 2.33.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.75 by $0.87. Bio-Rad Laboratories had a net margin of 8.59% and a return on equity of 3.54%. The firm had revenue of $651.00 million for the quarter, compared to analysts’ expectations of $623.99 million. During the same period last year, the firm earned $2.61 earnings per share. The business’s revenue for the quarter was down .1% on a year-over-year basis. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wells Fargo & Company increased their price objective on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Citigroup boosted their target price on Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings raised Bio-Rad Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. Royal Bank Of Canada raised their price target on Bio-Rad Laboratories from $320.00 to $370.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Finally, Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $343.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a life science research and clinical diagnostics company headquartered in Hercules, California. Founded in 1952 by David and Alice Schwartz, the company develops, manufactures and markets products used by academic, pharmaceutical, biotechnology, healthcare and government customers.

Its Life Science segment provides instruments, reagents, consumables and software for applications including genomics, digital PCR, gene expression analysis, protein purification, cell biology and biopharmaceutical quality control.